secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001562762-24-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B
--------------------------------------------------------------------------------

- Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.
- Full year 2023 sales ~$1.567B, up 53.2% as-reported over prior year.
- Legacy Globus Q4 revenue $302.9M (+10.4% YoY); full year $1.152B (+12.7%).
- FY2024 revenue guidance $2.450-2.475B; non-GAAP EPS guidance $2.68-$2.70.
- Completed NuVasive merger Sept 1, 2023; integration on track with strong sales retention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/0001562762-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/gmed-20240110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer